Should I buy or sell IceCure Medical stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IceCure Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ICCM shares. View ICCM analyst ratings or view top-rated stocks .

What is IceCure Medical's stock price target for 2024?

2 brokerages have issued 12 month price targets for IceCure Medical's shares. Their ICCM share price targets range from $2.90 to $3.00. On average, they anticipate the company's stock price to reach $2.95 in the next twelve months. This suggests a possible upside of 137.9% from the stock's current price. View analysts price targets for ICCM or view top-rated stocks among Wall Street analysts .

How have ICCM shares performed in 2024?

IceCure Medical's stock was trading at $1.07 at the beginning of the year. Since then, ICCM stock has increased by 15.9% and is now trading at $1.24. View the best growth stocks for 2024 here .

Are investors shorting IceCure Medical?

IceCure Medical saw a increase in short interest in March. As of March 31st, there was short interest totaling 353,600 shares, an increase of 45.7% from the March 15th total of 242,700 shares. Based on an average daily volume of 492,500 shares, the days-to-cover ratio is presently 0.7 days. Currently, 1.8% of the shares of the stock are sold short. View IceCure Medical's Short Interest .

When is IceCure Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our ICCM earnings forecast .

How were IceCure Medical's earnings last quarter?

IceCure Medical Ltd (NASDAQ:ICCM) posted its earnings results on Wednesday, April, 3rd. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The business earned $1.26 million during the quarter. IceCure Medical had a negative trailing twelve-month return on equity of 86.96% and a negative net margin of 453.76%. During the same period in the prior year, the business earned ($0.11) EPS.

How do I buy shares of IceCure Medical?

Shares of ICCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ICCM

IceCure Medical (ICCM) Stock Price, News & Analysis

→ Start loving Mondays like this (From DTI) (Ad)

Free ICCM Stock Alerts

$1.24

-0.05 (-3.88%)

(As of 01:21 PM ET)

Compare

Today's Range: $1.23
▼
$1.28
50-Day Range: $1.18
▼
$1.43
52-Week Range: $0.52
▼
$1.57

Volume: 70,910 shs
Average Volume: 679,114 shs
Market Capitalization: $56.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.95

Get IceCure Medical alerts:

IceCure Medical MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 137.9% Upside
$2.95 Price Target
Short Interest: Healthy
1.76% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.48
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.28) to ($0.27) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.49 out of 5 stars

Medical Sector

689th out of 914 stocks

Surgical & Medical Instruments Industry

71st out of 94 stocks

3.5

Analyst's Opinion

Consensus Rating
IceCure Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
IceCure Medical has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.76% of the float of IceCure Medical has been sold short.
Short Interest Ratio / Days to Cover
IceCure Medical has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in IceCure Medical has recently increased by 45.69%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
IceCure Medical does not currently pay a dividend.
Dividend Growth
IceCure Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ICCM.

2.0

News and Social Media Coverage

News Sentiment
IceCure Medical has a news sentiment score of -0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for IceCure Medical this week, compared to 1 article on an average week.
Search Interest
9 people have searched for ICCM on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.
MarketBeat Follows
5 people have added IceCure Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IceCure Medical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.44% of the stock of IceCure Medical is held by insiders.
Percentage Held by Institutions
Only 0.62% of the stock of IceCure Medical is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for IceCure Medical are expected to grow in the coming year, from ($0.28) to ($0.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IceCure Medical is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IceCure Medical is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IceCure Medical has a P/B Ratio of 4.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About IceCure Medical Stock (NASDAQ:ICCM)

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

ICCM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ICCM Stock News Headlines

April 17, 2024 | americanbankingnews.com

IceCure Medical (NASDAQ:ICCM) Receives Buy Rating from HC Wainwright

April 15, 2024 | finance.yahoo.com

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer

April 18, 2024 | Darwin (Ad)

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)

April 8, 2024 | americanbankingnews.com

IceCure Medical Ltd (NASDAQ:ICCM) Expected to Earn FY2024 Earnings of ($0.26) Per Share

April 8, 2024 | americanbankingnews.com

Q1 2024 EPS Estimates for IceCure Medical Ltd Raised by HC Wainwright (NASDAQ:ICCM)

April 6, 2024 | markets.businessinsider.com

Icecure Medical: Strong Buy on Impressive Q4 Revenue and Promising Regulatory Milestones

April 5, 2024 | seekingalpha.com

IceCure Medical Ltd. (ICCM) Q4 2023 Earnings Call Transcript

April 4, 2024 | uk.investing.com

IceCure seeks FDA clearance for new cryoablation system

April 18, 2024 | Darwin (Ad)

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

April 3, 2024 | prnewswire.com

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

April 2, 2024 | prnewswire.com

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes

March 27, 2024 | prnewswire.com

IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024

March 19, 2024 | markets.businessinsider.com

IceCure Medical: ICE3 Cryoablation Breast Cancer Study Shows Positive Results

March 19, 2024 | finance.yahoo.com

IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy

March 12, 2024 | prnewswire.com

IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes

March 7, 2024 | prnewswire.com

IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference

March 7, 2024 | prnewswire.com

IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference

March 5, 2024 | markets.businessinsider.com

IceCure Medical: Strong Buy on Promising Clinical Results and Positive FDA Developments

March 4, 2024 | prnewswire.com

IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024

February 27, 2024 | prnewswire.com

Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop

February 26, 2024 | prnewswire.com

Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer

February 24, 2024 | msn.com

IceCure Medical (ICCM) Price Target Increased by 5.85% to 3.14

February 15, 2024 | finance.yahoo.com

IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan

February 15, 2024 | prnewswire.com

IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan

January 30, 2024 | msn.com

FDA agrees to review IceCure request for De Novo classification

January 30, 2024 | finance.yahoo.com

U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer

January 29, 2024 | finance.yahoo.com

IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class

See More Headlines

Receive ICCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IceCure Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/03/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/27/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:ICCM
CUSIP: N/A
CIK: 1584371
Web: www.icecure-medical.com
Phone: 972-4623-0333
Fax: 972-4623-0222
Employees: 65
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.95
High Stock Price Target: $3.00
Low Stock Price Target: $2.90
Potential Upside/Downside: +128.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,650,000.00
Net Margins: -453.76%
Pretax Margin: -453.76%
Return on Equity: -86.96%
Return on Assets: -68.63%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 3.66
Quick Ratio: 3.08

Sales & Book Value

Annual Sales: $3.23 million
Price / Sales: 18.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.27 per share
Price / Book: 4.78

Miscellaneous

Outstanding Shares: 45,620,000
Free Float: 44,510,000
Market Cap: $58.85 million
Optionable: Not Optionable
Beta: 0.73

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Eyal Shamir (Age 63)
CEO & Director
Comp: $467.32k
Mr. Ronen Tsimerman CPA (Age 55)
CFO & COO
Comp: $331.8k
Ms. Tlalit Bussi Tel-Tzure (Age 53)
Vice President of Business Development & Global Marketing
Comp: $279.34k
Ms. Merav Nir Dotan (Age 55)
Vice President of Human Resources
Comp: $197.96k
Ms. Galit Malik (Age 51)
Vice President of Operations & Service

Key Competitors

View All Competitors

Institutional Ownership

Citadel Advisors LLC
Sold 21,522 shares on 2/15/2024
Ownership: 0.112%

View All Institutional Transactions

ICCM Stock Analysis - Frequently Asked Questions

Should I buy or sell IceCure Medical stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IceCure Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ICCM shares.
View ICCM analyst ratings or view top-rated stocks.
What is IceCure Medical's stock price target for 2024?: 2 brokerages have issued 12 month price targets for IceCure Medical's shares. Their ICCM share price targets range from $2.90 to $3.00. On average, they anticipate the company's stock price to reach $2.95 in the next twelve months. This suggests a possible upside of 137.9% from the stock's current price.
View analysts price targets for ICCM or view top-rated stocks among Wall Street analysts.
How have ICCM shares performed in 2024?: IceCure Medical's stock was trading at $1.07 at the beginning of the year. Since then, ICCM stock has increased by 15.9% and is now trading at $1.24.
View the best growth stocks for 2024 here.
Are investors shorting IceCure Medical?: IceCure Medical saw a increase in short interest in March. As of March 31st, there was short interest totaling 353,600 shares, an increase of 45.7% from the March 15th total of 242,700 shares. Based on an average daily volume of 492,500 shares, the days-to-cover ratio is presently 0.7 days. Currently, 1.8% of the shares of the stock are sold short.
View IceCure Medical's Short Interest.

When is IceCure Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our ICCM earnings forecast.
How were IceCure Medical's earnings last quarter?: IceCure Medical Ltd (NASDAQ:ICCM) posted its earnings results on Wednesday, April, 3rd. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The business earned $1.26 million during the quarter. IceCure Medical had a negative trailing twelve-month return on equity of 86.96% and a negative net margin of 453.76%. During the same period in the prior year, the business earned ($0.11) EPS.
How do I buy shares of IceCure Medical?: Shares of ICCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ICCM) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial